Stock comparison
LeMaitre Vascular
Veeva Systems
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
VEEV
Veeva Systems
Market cap
$26.07B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | VEEV | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 66B | LMAT |
| Benjamin Graham | 89A | 81A | LMAT |
| Philip Fisher | 81C | 77B | LMAT |
| Peter Lynch | 67B | 60C | LMAT |
| Joel Greenblatt | 56D | 52C | LMAT |
| Charlie Munger | 68D | 62C | LMAT |
| Terry Smith | 69D | 65D | LMAT |
Side-by-side metrics
| Metric | LMAT | VEEV |
|---|---|---|
| Market cap | $2.23B | $26.07B |
| P/E (TTM) | 37.1x | 28.7x |
| EV/EBIT | 36.6x | 26.9x |
| ROIC (TTM) | 9.43% | 9.48% |
| Gross margin | 72.39% | 75.53% |
| Net margin | 24.35% | 28.44% |
| Revenue CAGR 5y | 12.75% | 14.63% |
| EPS CAGR 5y | 19.04% | 18.76% |
| Debt / Equity | 0.5x | 0.0x |
| Dividend yield | 0.84% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
VEEV leads on
- Debt / Equity0.0xvs 0.5x+97%
- Market cap$26.07Bvs $2.23B+91%
- EV/EBIT26.9xvs 36.6x+27%
- P/E (TTM)28.7xvs 37.1x+23%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.